Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy.

ABSTRACT: Influenza A virus infection is a major global health concern causing significant mortality, morbidity, and economic loss. Antiviral chemotherapeutics that target influenza A virus are available; however, rapid emergence of drug-resistant strains has been reported. Consequently, there is a burgeoning need to identify novel anti-influenza A drugs, particularly those that target host gene products required for virus replication, to reduce the likelihood of drug resistance. In this study, a small interfering RNA (siRNA) screen was performed to identify host druggable gene targets for anti-influenza A virus therapy. The host organic anion transporter-3 gene (OAT3), a member of the SLC22 family of transporters, was validated as being required to support influenza A virus replication. Probenecid,

SUBMITTER: Perwitasari O 

PROVIDER: S-EPMC3535968 | biostudies-literature | 2013 Jan

REPOSITORIES: biostudies-literature